---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037216"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T11:15:27.030747+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acadia Q2 net income $1.1M; DAYBUE launch strong with $23.2M sales; guides Q3 DAYBUE $45-55M

## Summary
- Q2 net income of $1.1M ($0.01/share) vs net loss of $34.0M in prior year; total product sales $165.2M.
- DAYBUE (trofinetide) first full quarter of sales: $23.2M; expanded licensing deal with Neuren for global rights.
- NUPLAZID Q2 sales $142.0M, +5.5% YoY; full year guidance raised to $530-545M.
- R&D expenses decreased to $58.8M; SG&A increased to $96.0M due to DAYBUE launch costs.
- Appointed Dr. Kevin R. Oliver as SVP, Chief Business Officer; Phase 3 negative symptoms schizophrenia trial enrollment complete, results Q1 2024.

## SEC filing metadata
- accession: 0000950170-23-037216
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017023037216/0000950170-23-037216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017023037216/acad-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037216
- JSON: https://secwatch.observer/filing/0000950170-23-037216.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037216.txt

## Key facts
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported the six months ended June 30, 2023 results: revenue $283.7 million, net income a net loss of $41.9 million, or $0.26 per common share, EPS $0.26 per common share.
  - Period: the six months ended June 30, 2023
  - Revenue: $283.7 million
  - Net income: a net loss of $41.9 million, or $0.26 per common share
  - EPS: $0.26 per common share
  - Result: reported results
  source text: Total net product sales, comprised of NUPLAZID and DAYBUE were $165.2 million for the three months ended June 30, 2023, and were $283.7 million for the six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000095017023037216/0000950170-23-037216-index.htm
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $165.2 million, net income $1.1 million, or $0.01 per common share, EPS $0.01 per common share.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $165.2 million
  - Net income: $1.1 million, or $0.01 per common share
  - EPS: $0.01 per common share
  - Result: reported results
  source text: Total net product sales, comprised of NUPLAZID and DAYBUE were $165.2 million for the three months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000095017023037216/0000950170-23-037216-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.